Nautilus Neurosciences, Inc. Announces Co-Promotion Agreement for Lorzone™
6/12/2013 10:28:59 AM
More...
|
Eric Liebler, Founder and Former President of Nautilus Neurosciences, Inc., Joins ElectroCore
1/9/2013 7:33:13 AM
More...
|
Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA(R) for the Acute Treatment of Migraine
3/20/2012 8:53:37 AM
More...
|
Nautilus Neurosciences, Inc. Announces New Patent Issued
2/1/2012 9:52:06 AM
More...
|
Nautilus Neurosciences, Inc. Appoints Peter Lankau as Executive Chairman
11/8/2011 8:51:01 AM
More...
|
Nautilus Neurosciences, Inc. Selects Mission3 OnDemand Virtual Data Room
8/19/2011 9:18:42 AM
More...
|
Nautilus Neurosciences, Inc. and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA(TM) (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
11/16/2010 6:43:12 AM
More...
|
Nautilus Neurosciences, Inc.: New Analysis of CAMBIA(TM) Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology
10/26/2010 7:13:24 AM
More...
|
Nautilus Neurosciences, Inc. and Mission Pharmacal Company Announce Exclusive Co-Promotion Agreement for CAMBIA(TM) (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market
10/6/2010 6:53:35 AM
More...
|
Nautilus Neurosciences, Inc. and APR Applied Pharma Research S.A. Announce Extension of Patent Protection for CAMBIA(TM) (Diclofenac Potassium for Oral Solution) Through 2026
9/8/2010 12:07:15 PM
More...
|
|